About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 4NCT04691362

Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty

To find noninferiority relationship between oral and intravenous administration of tranexamic acid on peroperative and postoperative blood loss and serum concentration during primary total hip arthrop...

Lead sponsor: University of Liege•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Liege

Tranexamic acid is an anti-fibrinolytic drug, recommended in total hip arthroplasty to reduce peroperative and postoperative hemorrhagic complications. The original character of our study lies in the serum dosage of tranexamic acid, allowing to correlate the primary objective (blood loss) with this one. The investigators will focus on the reduction of the risks associated with the administration of intravenous medicines, the economic aspect and the ease of use.

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•\- ASA physical status 1, 2 and 3 scheduled for primary total hip arthroplasty

Exclusion Criteria

•Renal failure with serum creatinine level higher than 1,40 mg/dL
•Thromboembolic events in last 12 months before surgery
•Pregnancy
•Congenital or acquired coagulation diseases
•History of gastric surgery that could lead to malabsorption
•Diabetic gastro-paresis

Related studies

Innovative Technologies for Salvage Procedures of Failed Treatments of Osteoarthritis: Biomimetics Solutions (CustomPN)

NCT06527664 · Bone Loss, Hip Prosthesis Infection, and more

Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty

NCT05845021 · Osteoporosis, Arthroplasty Complications, and more

l Investigation of Robotic-assisted TKA (RA-TKA) With Skywalker and Evolution Medial Pivot Knee (eMP Knee)

NCT06969222 · Knee Arthropathy, Arthroplasty Complications, and more

The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty

NCT05216666 · Hip Osteoarthritis, Muscle Weakness, and more

Effect of Game Activity and Stress Ball on Anxiety and Vital Signs

NCT06523413 · Anxiety, Arthroplasty Complications

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 15, 2022Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment230

Start dateJan 2021

Last updatedDec 15, 2022

Condition

Hemorrhage Postoperative Total Blood Loss Arthroplasty Complications

Locations shown

CHU de Liège

Liège

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 15, 2022Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions